We are live on ! Find out more
ARTL icon

Artelo Biosciences
ARTL

4 hedge funds and large institutions have $76.4K invested in Artelo Biosciences in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.44% more ownership

Funds ownership: 1.37% → 1.82% (+0.44%)

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

3% less capital invested

Capital invested by funds: $78.4K → $76.4K (-$2.01K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$56.1K
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$11.1K
3
UBS Group
UBS Group
Switzerland
+$300

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
-$40.9K
2
TRCT
Tower Research Capital (TRC)
New York
-$4.8K
3
JP Morgan Chase
JP Morgan Chase
New York
-$611

ARTL Hedge Fund Activity: Q3 2023 in Review

4 of the 6,311 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2023, worth a combined $76.4K — down 2.6% from $78.4K a quarter earlier.

Fund positioning in ARTL was balanced in Q3 2023: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $56.1K. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $40.9K sold.

  • 4 institutional investors held Artelo Biosciences (ARTL) as of Q3 2023, unchanged from Q2 2023.
  • Funds reported $76.4K of Artelo Biosciences stock for Q3 2023, down 2.6% quarter-over-quarter.
  • 2 funds opened new Artelo Biosciences positions in Q3 2023 and 2 closed out, a net change of 0 holders.
  • The largest Artelo Biosciences buyer in Q3 2023 was HRT Financial, an estimated $56.1K added.
  • The largest Artelo Biosciences seller in Q3 2023 was Two Sigma Advisers, an estimated $40.9K sold.

Based on aggregated 13F filings for Q3 2023.